


Strengthening PHEMCE through stakeholder engagement and sustainable investment



Bruce Altevogt, PhD
Vice President and Head, External Medical Engagement
Hospital Business Unit, Biopharmaceuticals Group
Pfizer Inc.

Legal Disclaimer

- This presentation contains statements that constitute personal views and opinions
- Although the presenter is employed in a pharmaceutical company, the information contained here is not intended to convey the company position
- No official support by Pfizer has been provided or should be inferred

Four Opportunities

- End users must be part of the process from the beginning
- PHEMCE needs to be structured to support agile response and long-term portfolio management
- Investments need to be sustainable and predictable
- Prioritize rigor and celebrate failures

End users must be part of the process from the beginning

- Establish mechanisms to enable end-to-end engagement with the end users- patients, providers, and public health officials
- These end users who will be needing and using the products and must be involved in the shared decision-making process

PHEMCE needs to be structured to support agile response and long-term portfolio management

- Serve as more than a coordinating body by embracing a strategy that supports long-term investment and agile response
 - Ensure programs do not compete for resources
 - Establish lead agencies for programs to ensure progress and accountability
 - Leverage lessons from the private sector on portfolio management to help manage and assess PHEMCE programs
 - Dedicated portfolio management teams assess unmet need and scientific risk/probability of success

Investments need to be sustainable and predictable

- Large companies that have the resources to support large-scale manufacturing and global access as well as venture capital need to see investments as providing a ROI in a similar range as other therapeutic areas.
- Lack of investment in antibiotics is a case study of what will happen if the ROI is not sustained.
 - We have not had a new class of gram-negative antibiotics since the 1980's with multiple companies leaving the space and/or going bankrupt*

Prioritize rigor and celebrate failures

- R&D is a very complex process. Important to have rigor behind programs.
 - Establish a culture that celebrates successes as much as it celebrates failures. This will help ensure only the most impactful programs will proceed
 - Can bring in experts from industry to help review programs and ensure decisions are based on the scientific need, taking into account a risk-reward framework.